Clinical Significance and Prognostic Value of the Expression of Fibronectin Type III Domain Containing 3B in Pancreatic Carcinoma

doi:10.21203/rs.3.rs-35308/v1

Download PDF

Research article

Clinical Significance and Prognostic Value of the Expression of Fibronectin Type III Domain Containing 3B in Pancreatic Carcinoma

https://doi.org/10.21203/rs.3.rs-35308/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background: Pancreatic carcinoma (PC) is one of the most aggressive cancers affecting human health. Identifying candidate biomarkers is essential for the early diagnosis and good prognosis of PC. Fibronectin type III domain containing 3B (FNDC3B) promotes many types of cancer, but its role in pancreatic cancer is not clear. The purpose of this study was to investigate the relationship between the expression of FNDC3B and incidence of PC.

Methods: We downloaded data related to the levels of FNDC3B mRNA in patients of PC from the Cancer Genome Atlas (TCGA) database, and conducted in-depth research on this data and its clinical significance through the R tools. We used GO and KEGG enrichment analyses to study the genes and signaling pathways that may be regulated by FNDC3B.

Results: The results showed that the level of FNDC3B mRNA in PC tissues was higher than that in the normal tissues, and this was associated with proliferation and lymph node metastases of PC. Increased levels of FNDC3B mRNA also predict poor prognosis for the patients with PC. In addition, enhanced levels of FNDC3B mRNA were involved in the regulation of cell junction, tissue and epithelial cell migration, and several signal transduction pathways, including notch, TGF-β, VEGF, and Wnt.

Conclusions: In short, high levels of FNDC3B mRNA may be associated with progression of PC and indicate a poor prognosis in patients with PC.

Cancer Biology

Oncology

fibronectin type III domain containing 3B

pancreatic carcinoma

Gene set enrichment analysis

Pancreatic carcinoma (PC) is a common gastrointestinal tumor with a high degree of malignancy and a poor prognosis. The 5-year survival rate is less than 6% [1], and its morbidity and mortality have been increasing. It is estimated that by the year 2020, the number of new cases of PC in the world will be approximately 420,000 and the number of deaths due to it will be approximately 410,000 [2]. By 2030, PC will become the second most common malignant tumor, with high mortality rate [3]. Genes and environment are two important causes of PC. Many unhealthy lifestyle choices, such as smoking, unbalanced diet, and obesity are also important risk factors for PC. Previous epidemiological studies have shown that chronic pancreatitis increases the risk of pancreatic cancer [4]. Due to the lack of identifiable clinical symptoms and specific markers at the early stages, the tumors escape early detection, grow rapidly and metastasize early. Because of this, more than 90% of patients are clinically diagnosed only when the pancreatic cancer is in the middle and advanced stages, missing the best time for treatment [1]. Therefore, early detection, diagnosis and treatment, are the key to reduce the mortality rate of the PC, and to improve the quality of life of the patients. Identification of specific markers to facilitate early diagnosis of PC is an active area of research at present [5–7].

Fibronectin type III domain containing 3B (FNDC3B), is a protein of the FNDC3 family that includes FNDC3A, FNDC3B and FNDC3C, also known as factor for adipocyte differentiation 104 (FAD104), it contains a proline-rich region, and 9 fibronectin type III structures domain and a transmembrane region, and is a regulator of adipocyte and osteoblast differentiation [8–12]. Fibronectin type III (FNIII) domain of FNDC3B serves as a tail sheath, integrates with different proteins, and plays an important role in cell adhesion and growth signaling [9, 13, 14]. Homozygous disruption of FNDC3B causes mice to die at birth from abnormalities in the lungs [14, 15], and has a significant effect on the adhesion, proliferation and migration of mouse embryonic fibroblasts [9, 16]. Cell adhesion is important in tumorigenesis because it provides tumor cells with the necessary contacts and cell-matrix interactions needed for cell signaling, proliferation, and migration [17]. FNDC3B is one of the most common genes up-regulated in cancer tissues, regardless of the cancer type and tumor origin [18]. Recent studies have found that FNDC3B is highly expressed in breast cancer, esophageal cancer, glioblastoma, and hepatocellular carcinoma, and is associated with cancer cell proliferation, invasion and metastasis [19–23]. Therefore, we hypothesized that FNDC3B promotes cell migration and tumorigenesis in PC. In this study, our bioinformatics analyses explored the role of FNDC3B in pancreatic cancer, as well as the processes and signaling pathways it may regulate.

Evaluation of transcription level of FNDC3B in PC patients

RNA-sequence data of PC patients along with individual clinical information were downloaded from the Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). An in-depth analysis of FNDC3B expression at the transcriptional level in unpaired PC samples was performed by R version 3.6.2 (https://cran.r-project.org/src/base/R-3/) using the limma package version 3.8 (https://bioconductor.org/packages/release/bioc/html/limma.html) and Statistical Computing version 3.5.1 software.

Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis

According to the median value of FNDC3B mRNA expression, PC patients from the TCGA database were divided into high FNDC3B mRNA group and low FNDC3B mRNA group. Signaling pathways and molecules related to FNDC3B expression in PC patients were studied by GO and KEGG enrichment analysis (http://www.broadinstitute.org/gsea/index.jsp).

Evaluation of overall survival rate by KM curves

The overall survival rate in PC patients from both high and FNDC3B mRNA groups was assessed by KM (Kaplan-Meier) curves and the log-rank test. Patients of PC who had over five years of survival were considered as with a long overall survival (OS) had, whereas those who died or experienced recurrence in less than 2 years were classified as with a short OS. A value of P < 0.05 was considered statistically significant.

Statistical analysis

The mRNA levels of FNDC3B in patients of PC are expressed as the mean ± standard deviation. Student's t-test (unpaired) was used for comparison between two groups, and analysis of variance (ANOVA) was used to identify significant differences between multiple groups. All statistical analyses were performed with SPSS 21.0 software (IBM, Armonk, NY, USA). A P value < 0.05 was considered statistically significant.

AUC value determination for the ROC curve

The area under the curve (AUC) value was computed for the ROC curve to assess the discriminatory ability of FNDC3B expression in patients of PC, with distinct clinical parameters.

Gene set enrichment analysis of FNDC3B expression in patients of PC

To investigate the effect of upregulated FNDC3B expression in PC, we performed gene set enrichment analysis of FNDC3B expression in patients, with corresponding clinical information from TCGA datasets. Our results showed that the expression of FNDC3B was significantly upregulated in patients with advanced PC and distant metastasis. We also found that the mRNA level of FNDC3B was higher in patients of PC with good OS than in those with poor prognosis, whereas no significant difference in the expression of FNDC3B was observed in patients according to age, sex and lymph node metastasis. These results suggest that upregulation of FNDC3B is associated with distant metastasis of PC and predicts a poor prognosis for patients (Fig. 1).

Clinical and molecular characteristics of PC with high FNDC3B expression

We further investigated the mRNA expression of FNDC3B in patients with PC from the TCGA database, and found that the mRNA level of FNDC3B was significantly higher in the cancer cells than in corresponding noncancerous normal tissues (Fig. 2A). In grade (G stage) G2 and G3, FNDC3B mRNA levels were higher compared to G1 (Fig. 2D). In the TNM stage II, the level of FNDC3B mRNA was higher than in stage I (Fig. 2E). In patients older than 65 years, FNDC3B mRNA levels were higher than in younger patients (Fig. 2C). In the advanced tumor stage (T stage) T3, the FNDC3B mRNA level was higher than in T2 (Fig. 2F). Gender-wise, the FNDC3B mRNA level in male patients was comparable to that in female patients (Fig. 2B). These results showed a significant association of higher expression of FNDC3B with advanced age, G stage, tumor stage, and TNM stage, but not with the sex of the patient.

Upregulation of FNDC3B mRNA levels indicates poor prognosis for patients of PC

PC patients from the TCGA data set were divided into two groups, based on the median expression of FNDC3B mRNA, to investigate the prognostic role of FNDC3B in PC. We found that level of FNDC3B mRNA was higher in patients with lymph node metastasis, and poor OS, and patients who had died (Fig. 3A, 3C, 3D), whereas it was lower in patients with distant metastasis (Fig. 3B). Overall, these data suggested that upregulation of FNDC3B mRNA levels indicated poor prognosis for patients with PC. This may serve as a potential indicator of prognosis in patients with PC.

The ROC curve shows that high levels of FNDC3B mRNA is associated with PC

Using ROC curves, we analyzed whether expression levels of FNDC3B mRNA can effectively distinguish PC patients with different pathological parameters, to confirm that FNDC3B mRNA expression is related to cancer cell proliferation and poor prognosis. FNDC3B mRNA expression could be used to distinguish PC tissues from normal tissues, with an AUC of 0.9510 (95% CI: 0.9253–0.9767; P < 0.0001) (Fig. 4A). We also found a significant difference in FNDC3B expression in PC subgroups, including subgroups of G stage (G1/G2, AUC = 0.6375, P = 0.0278; G1/G3, AUC = 0.6856, P = 0.0072), TNM stage (TNM stage I/TNM stage II, AUC = 0.6599, P = 0.0205), T stage (T2/ T3, AUC = 0.6223, P = 0.0559), status (Living/dead, AUC = 0.6236, P = 0.0052) lymph node metastasis (N0/N1 + NX, AUC = 0.6259, P = 0.0112), and distant metastasis (M0/M1 + MX, AUC = 0.6392, P = 0.0017; Fig. 4B-4I). These results confirm that higher levels of FNDC3B mRNA is associated with cancer proliferation, metastasis and poor prognosis in PC.

High FNDC3B mRNA level correlates with short OS in PC patients

KM survival analysis was used to determine the correlation of level of FNDC3B mRNA with OS of the patients with PC. Patients with higher levels of FNDC3B mRNA had shorter OS than those with lower levels (Fig. 5A, P = 0.0025). Moreover, we analyzed the association between OS and FNDC3B mRNA level in various clinical subgroups of PC. As shown in Fig. 5B-5G, compared with patients with low FNDC3B expression, males (Fig. 5B, P = 0.0130), age > 65 years (Fig. 5C, P = 0.0378), age ≤ 65 years (Fig. 5D, P = 0.0060), G1 + G2 stage (Fig. 5E, P = 0.0153), stages I + II (Fig. 5F, P = 0.0015) and T3 + T4 stage (Fig. 5G, P = 0.0371) patients with high FNDC3B mRNA level exhibited a shorter OS time. All these results indicate that level of FNDC3B mRNA correlates with short OS.

GO enrichment analysis shows that FNDC3B mRNA level is associated with genes involved in regulation of cell junction, tissue migration and epithelial cell migration

To identify the molecules regulated by FNDC3B, we performed GO enrichment analysis. We found that higher level of FNDC3B mRNA was associated with regulation of cell junction, tissue migration and epithelial cell migration (Fig. 6A). Furthermore, the it was also strongly associated with HIF1A, ADAM17, CORO1C, ITGB1, LIMS1, MAP4K4, PDLIM5 and PIK3CA (Fig. 6B). These results indicate that high level of FNDC3B mRNA is associated with junction and migration of PC cells.

KEGG enrichment analysis shows that FNDC3B is associated with pathways related to signal transduction

To investigate the association between FNDC3B and signaling pathways, we performed KEGG enrichment analysis. The results showed that FNDC3B expression was positively associated with PC. We also found that FNDC3B expression was significantly enriched in four main well-studied signaling pathways in PC, including the notch, TGF-β, VEGF and Wnt signaling pathways (Fig. 7A). Moreover, the expression of genes in these four signaling pathways, including ACVR1, BMPR2, CTNNB1, ITGAV, MAPK1, NOTCH2, PIK3CA and ROCK1, was associated with the level of FNDC3B mRNA (Fig. 7B). All these data suggest that level of FNDC3B mRNA is associated with four main signaling pathways in PC.

PC is an aggressive disease with almost no symptoms until the cancer is well established [24, 25]. Carbohydrate antigen 19 − 9 is the only diagnostic marker approved by the FDA, but its diagnostic potential is limited due to its limited sensitivity and specificity [26, 27]. Therefore, screening new tumor biomarkers is important for the early diagnosis and targeted treatment of PC. In this study, by analyzing the TCGA database, it was found that the level of FNDC3B mRNA was increased in tissues involved in PC, which indicates that FNDC3B may be involved in PC progression.

Many studies have confirmed that FNDC3B promotes tumor progression. Lin et al. found that FNDC3B enhances the migration and metastasis of hepatocellular carcinoma cells by binding to annexin A2 (ANXA2) through the FNIII1-4 domain [14]. Cai et al. confirmed that FNDC3B increases the proliferation of liver cancer cells by inducing epithelial to mesenchymal transition (EMT) to activate the PI3K / AKT, Rb1 and TGF-β pathways [28]. Studies have found that miR-129-5p binds to the 3’UTR of FNDC3B and down-regulates its expression, leading to inhibition of the proliferation, invasion and migration of glioma cells [21]. Silencing FNDC3B expression in tongue squamous cell carcinoma cells can inhibit the occurrence of EMT, suggesting that FNDC3B plays an important role in promoting the proliferation, invasion and migration of tongue squamous cell carcinoma cells [29]. Present study found that FNDC3B mRNA levels had increased in PC tissues with lymph node metastasis. In addition, high levels of FNDC3B mRNA in PC promote cell junction, tissue migration, epithelial cell migration, and positively regulate several signaling pathways, including notch, TGF-β, VEGF and Wnt. This indicates that FNDC3B may promote migration of PC cells. However, Zhang et al. found that miR-143, upregulated by NF-κB transcription, inhibited the expression of FNDC3B, which promoted the metastasis of HBV-related liver cancer [30]. Fan et al. also found that miR-143 was significantly up-regulated during the differentiation of prostate cancer stem cells, and that the increased miR-143 could inhibit the expression of FNDC3B and promote the metastasis of prostate cancer [31]. Studies have shown that tumor cells can promote tumor invasion and metastasis by inducing EMT. During this process, the expression of β-catenin is up-regulated, thereby inhibiting the transcription of E-cadherin, weakening the cell-to-cell connection and spindle-shaped cell transformation, which further enhances its ability to migrate, accompanied by down-regulation of the expression of epithelial markers and up-regulation of interstitial markers [32, 33].

Overall, our results highlight the involvement of FNDC3B mRNA in tumorigenesis and metastasis. These results need to be further verified by testing PC tissues and in vivo and in vitro studies.

In conclusion, this study shows that FNDC3B plays a vital role in PC proliferation and metastasis, opening up new avenues for targeted treatment of PC. In addition, it can regulate biological processes, such as cell junction, tissue migration, epithelial cell migration, notch-, TGF-β-, VEGF-, and Wnt-signaling pathways, by regulating the expression of HIF1A, ADAM17, CORO1C, ITGB1, LIMS1, MAP4K4, PDLIM5, PIK3CA, ACVR1, BMPR2, CTNNB1, ITGAV, MAPK1, NOTCH2, PIK3CA and ROCK1. Since the expression of FNDC3B is related to the survival rate of patients, inhibiting FNDC3B in tumor tissue may provide an effective treatment strategy.

Gene ontology; KEGG:Kyoto Encyclopedia of Genes and Genomes; TCGA:the Cancer Genome Atlas; EMT:epithelial to mesenchymal transition; ANXA2:annexin A2; AUC:area under the curve; PC:pancreatic carcinoma; FNDC3B:Fibronectin type III domain containing 3B.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by Fujian Province Natural Science Foundation (grant number 2018J01266) and Joint Funds for the Innovation of Science and Technology, Fujian Province (grant number 2017Y9074).

Authors' contributions

LQM, XHL, KXD and XQK designed the study, downloaded data from TCGA, performed KEGG enrichment analysis and KM survival analysis, and drafted the manuscript. JLL and HHL were responsible for GO enrichment analysis and OS analysis. XYL and JG were responsible for ROC curve analysis. All authors read and approved the final manuscript for publication.

Acknowledgements

Not applicable.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.
Kirkegård J, Cronin-Fenton D, Heide-Jørgensen U, Mortensen FV. Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark. Gastroenterology. 2018;154(6):1729–36.
Bertsch T, Aschenneller C, Bewarder N, Beyrau R, Herrmann BL, Jansen E, Klapdor R, Klemm M, Meissner J, Pfeiffer S, et al. European proficiency study with control serum for the tumor marker CA 19 – 9 measured on different test systems. Clin Lab. 2013;59(1–2):185–92.
Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19 – 9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol. 2016;7(3):E45–51.
Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P, Sobczyk W, Kapalka A, Lampe P. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol. 2015;66(5):653–63.
Tominaga K, Kondo C, Johmura Y, Nishizuka M, Imagawa M. The novel gene fad104, containing a fibronectin type III domain, has a significant role in adipogenesis. FEBS Lett. 2004;577(1–2):49–54.
Nishizuka M, Kishimoto K, Kato A, Ikawa M, Okabe M, Sato R, Niida H, Nakanishi M, Osada S, Imagawa M. Disruption of the novel gene fad104 causes rapid postnatal death and attenuation of cell proliferation, adhesion, spreading and migration. Exp Cell Res. 2009;315(5):809–19.
Kishimoto K, Kato A, Osada S, Nishizuka M, Imagawa M. Fad104, a positive regulator of adipogenesis, negatively regulates osteoblast differentiation. Biochem Biophys Res Commun. 2010;397(2):187–91.
Katoh D, Nishizuka M, Osada S, Imagawa M. Fad104, a positive regulator of adipocyte differentiation, suppresses invasion and metastasis of melanoma cells by inhibition of STAT3 activity. PLoS One. 2015;10(2):e0117197–7.
Wang H-Y, McMahon C, Ali SM, Young LE, Yekezare S, Ross JS, Ball ED. Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia. Br J Haematol. 2016;172(6):987–90.
Cheng CK, Wang AZ, Wong THY, Wan TSK, Cheung JS, Raghupathy R, Chan NPH, Ng MHL. FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia. Blood. 2017;129(19):2705–9.
Lin C-H, Lin Y-W, Chen Y-C, Liao C-C, Jou Y-S, Hsu M-T, Chen C-F. FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma. Oncotarget. 2016;7(31):49498–508.
Kishimoto K, Nishizuka M, Ueda T, Kajita K, Ugawa S, Shimada S, Osada S, Imagawa M. Indispensable role of factor for adipocyte differentiation 104 (fad104) in lung maturation. Exp Cell Res. 2011;317(15):2110–23.
Urtreger AJ, Werbajh SE, Verrecchia F, Mauviel A, Puricelli LI, Kornblihtt AR. Bal de Kier Joffé ED: Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential. Oncol Rep. 2006;16(6):1403–10.
van Kilsdonk JWJ, van Kempen LCLT, van Muijen GNP, Ruiter DJ, Swart GWM. Soluble adhesion molecules in human cancers: sources and fates. Eur J Cell Biol. 2010;89(6):415–27.
Lu Y, Yi Y, Liu P, Wen W, James M, Wang D, You M. Common human cancer genes discovered by integrated gene-expression analysis. PLoS One. 2007;2(11):e1149–9.
Peng Y, Li H, Li X, Yu S, Xiang H, Peng J, Jiang S. MicroRNA-215 impairs adipocyte differentiation and co-represses FNDC3B and CTNNBIP1. Int J Biochem Cell Biol. 2016;79:104–12.
Yang Y, Li D, Yang Y, Jiang G. An integrated analysis of the effects of microRNA and mRNA on esophageal squamous cell carcinoma. Mol Med Rep. 2015;12(1):945–52.
Xu H, Hu Y, Qiu W. Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B. Biomed Pharmacother. 2017;87:405–11.
Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Oncotarget. 2015;6(28):26192–215.
Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011;19(3):347–58.
Zhang Y, Jiang H, Qin M, Su X, Cao Z, Wang J. TNIK serves as a novel biomarker associated with poor prognosis in patients with pancreatic cancer. Tumour Biol. 2016;37(1):1035–40.
Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2011;7(1):16–24.
Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19 – 9. Cancer. 2000;89(1):83–8.
Su S-B, Qin S-Y, Chen W, Luo W, Jiang H-X. Carbohydrate antigen 19 – 9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol. 2015;21(14):4323–33.
Cai C, Rajaram M, Zhou X, Liu Q, Marchica J, Li J, Powers RS. Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. Cell Cycle. 2012;11(9):1773–81.
Zhong Z, Zhang H, Hong M, Sun C, Xu Y, Chen X, Gao C, He M, Liu W, Liang J. FNDC3B promotes epithelial-mesenchymal transition in tongue squamous cell carcinoma cells in a hypoxic microenvironment. Oncol Rep. 2018;39(4):1853–9.
Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009;50(2):490–9.
Fan X, Chen X, Deng W, Zhong G, Cai Q, Lin T. Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer. 2013;13:61–1.
Lv Y-f, Dai H, Yan G-n, Meng G, Zhang X, Guo Q-n. Downregulation of tumor suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by the Wnt/GSK-3β/β-catenin/Snail signaling pathway. Cancer Lett. 2016;373(2):164–73.
Zhang T, Liang L, Liu X, Wu J-N, Chen J, Su K, Zheng Q, Huang H, Liao G-Q. TGFβ1-Smad3-Jagged1-Notch1-Slug signaling pathway takes part in tumorigenesis and progress of tongue squamous cell carcinoma. J Oral Pathol Med. 2016;45(7):486–93.

Download PDF

Version 1

posted

You are reading this latest preprint version

Clinical Significance and Prognostic Value of the Expression of Fibronectin Type III Domain Containing 3B in Pancreatic Carcinoma

Status:

Version 1

Abstract

Figures

Background

Methods

Statistical analysis

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Status:

Version 1